TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies

A new model, TxGNN, revolutionizes zero-shot drug repurposing by predicting treatments for diseases with no known therapies, offering improved accuracy and trust via interpretable AI explanations.

Atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights | Psychedelic Invest

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA

November 14, 2023

Illumina to lay off 10% of research and development team in bid to cut costs by $100 million

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its

June 26, 2023

BICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD

Biosero, a BICO company and developer of laboratory automation solutions to orchestrate scientific discoveries, has signed an agreement with a global life science company for

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.